Exploration of the Clinical Application of Almonertinib in the First-line Treatment of Patients With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer With Poor Performance Status
Sponsor study identifier
interventional
20
1 country
1
Study Start
January 1, 2022
Actual (reported)Primary Completion
December 28, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Most of the lung cancer patients treated in hospitals in China are in advanced stage, accounting for more than 2/3 of all lung cancer patients, and some of the patients have a poor performence status.At present, most of the patients included in clinical trials are patients with good PS score, and the NCCN guidelines for advanced lung cancer patients with poor performence status recommend the best supportive care.Therefore, the investigator wanted to explore the efficacy and safety of Almonertinib in lung cancer patients with poor performance status.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2022
Actual (reported)February 5, 2022
Actual (reported)April 24, 2023
Actual (reported)December 28, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
ORR
Objective Response Rate
24 months
Time of PS score change from 2~4 to 1
Time of performance status score change from 2\~4 to 1
6 months
PFS
24 months
OS
from baseline until death due to any cause, up to a maximum of approximately 4years
DCR
24 months
Safety: Dose-limiting toxicities
from the screening period to 28 days after treatment completion
Almonertinib, 110 mg, po, QD; 28 days every cycle
Almonertinib Mesilate Tablets
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Zhou Chengzhi
Guangzhou, Guangdong, 510120, China
Zhou Chengzhi, MD
The First Affiliated Hospital of Guangzhou Medical University
First Submitted
February 5, 2022
First Posted
April 24, 2023
Study Start
January 1, 2022
Actual (reported)Primary Completion
Contact the study team to confirm eligibility.
December 28, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 30, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 24, 2023
Record last verified: 2023-04
no plan
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: